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Angiotensin II causes cardiovascular injury in part by
aldosterone-induced mineralocorticoid receptor activation,
and it can also activate the mineralocorticoid receptor in the
absence of aldosterone in vitro. Here we tested whether
endogenous aldosterone contributes to angiotensin II/
salt-induced cardiac, vascular, and renal injury by the
mineralocorticoid receptor. Aldosterone synthase knockout
mice and wild-type littermates were treated with angiotensin
II or vehicle plus the mineralocorticoid receptor antagonist
spironolactone or regular diet while drinking 0.9% saline.
Angiotensin II/salt caused hypertension in both the knockout
and wild-type mice, an effect significantly blunted in the
knockout mice. Either genetic aldosterone deficiency or
mineralocorticoid receptor antagonism reduced cardiac
hypertrophy, aortic remodeling, and albuminuria, as well as
cardiac, aortic, and renal plasminogen activator inhibitor-1
mRNA expression during angiotensin II treatment.
Mineralocorticoid receptor antagonism reduced angiotensin
II/salt-induced glomerular hypertrophy, but aldosterone
deficiency did not. Combined mineralocorticoid receptor
antagonism and aldosterone deficiency reduced blood
urea nitrogen and restored nephrin immunoreactivity.
Angiotensin II/salt also promoted glomerular injury through
the mineralocorticoid receptor in the absence of aldosterone.
Thus, mineralocorticoid antagonism may have protective
effects in the kidney beyond aldosterone synthase inhibition.
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Interruption of angiotensin II (Ang II) signaling is an
established strategy to reduce cardiovascular and renal events
in high-risk populations.1,2 Clinical trials also demonstrate
that the addition of mineralocorticoid receptor (MR)
antagonism to angiotensin-converting enzyme (ACE) inhibi-
tion reduces mortality and cardiac and renal injury,3–5
suggesting that aldosterone contributes to Ang II–mediated
injury or alternatively that MR mechanisms may in part
be Ang independent. In this regard, the glucocorticoids
corticosterone or cortisol also bind to and activate the MR,
raising the possibility that MR antagonism exerts beneficial
effects that are independent of aldosterone or angiotensin.
The observation that MR antagonism reduces end-organ
damage even when endogenous aldosterone concentrations
are suppressed further supports such a possibility.6–8
Pharmacologic aldosterone synthase (AS) inhibition with
FAD-286 reduces Ang II–induced profibrotic gene expression
and cardiac and renal injury in rodent models of hyper-
tension.9,10 Because low levels of aldosterone remain in
the circulation during treatment with FAD-286, it is not
possible to exclude a permissive effect of aldosterone on
Ang II signaling and tissue injury. In vitro studies also suggest
that Ang II can activate the MR in the absence of
aldosterone.11,12 To investigate this in vivo, adrenalectomy
eliminates circulating aldosterone nonselectively, requiring
glucocorticoid replacement that may not mimic endogenous
production. The availability of As-deficient mice (As/)
results in complete aldosterone deficiency without impaired
glucocorticoid synthesis and permits investigators to dissect
out any contribution of aldosterone to Ang II–mediated
injury.13,14
We have previously used this model to determine the
contribution of endogenous aldosterone to the acute effects
of Ang II on inflammatory gene expression.13 This study tests
the hypothesis that endogenous aldosterone contributes to
chronic Ang II–induced pro-inflammatory gene expression
and target organ damage via the MR.
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RESULTS
Basic metabolic measurements
Aldosterone-deficient mice (As/) and wild-type (WT)
littermates were treated with Ang II (1 mg/h) or vehicle via
osmotic minipump plus the MR antagonist spironolactone
(SPL; 6 mg/kg/day) or regular chow for 8 weeks while
drinking 0.9% saline. Total body weight and lean body mass
were similar among the treatment groups. Serum potassium
was similar in the untreated As/ mice compared with WT
(5.4±0.6 vs. 5.1±0.3, P¼ 0.07), and among the treatment
groups (Table 1). Serum sodium, chloride, bicarbonate, and
corticosterone were also similar among the groups. Plasma
aldosterone increased during Ang II treatment in WT mice
and to an even greater extent during SPL treatment.
Aldosterone was below the detectable limits in all As/
mice (Po0.01 vs. each WT group).
Urinary sodium excretion increased during Ang II treat-
ment (Table 1). This response was blunted in As/ during both
normal chow and SPL treatment. Urinary potassium excretion
was not different among groups, except for an increase in the
As/-Ang II–SPL-treated mice. Changes in urinary Na/K
excretion paralleled those of urinary sodium excretion.
Blood pressure response to Ang II
Systolic blood pressure was similar at baseline (101.9±1.8
and 97.1±2.3 mm Hg in WT and As/, respectively;
P¼ 0.13). Vehicle treatment did not affect systolic blood
pressure (Figure 1). Ang II significantly increased systolic
blood pressure in both WT and As/ mice (Po0.05). The
pressor response to Ang II at post hoc testing was significantly
decreased in As/ mice in the presence (Po0.05) or absence
(Po0.05) of SPL. Systolic blood pressure was similar in
SPL-treated As/ and WT mice (P¼ 0.20).
Cardiac assessment
Ang II treatment significantly increased cardiac mass in WT
mice, but not in As/ mice (Figure 2a). SPL prevented the
effect of Ang II on cardiac mass in WT mice. Results were
similar when correcting heart weight by either body weight (not
shown) or tibia length. Ang II significantly increased cardiac
interstitial fibrosis in WT, and this was prevented in As/ mice
(Figure 2b). Ang II did not significantly increase interstitial
fibrosis in SPL-treated WT mice. Cardiac perivascular fibrosis
was markedly increased by Ang II treatment in WT mice. The
effect of Ang II was not significant in SPL-treated WT mice and
was almost entirely abrogated in As/ mice (Figure 2c and d).
Ang II increased aortic intima–media and adventitial
thickness in WT mice (Figure 3a–c; P¼ 0.002 for Ang II
effect, P¼ 0.05 for SPLAng II effect on adventitial
thickening). Either SPL or aldosterone deficiency attenuated
aortic pathologic changes. There was no additive effect of SPL
in aldosterone-deficient mice.
Kidney injury assessment
Blood urea nitrogen increased significantly during Ang II
treatment (Figure 4a). Neither SPL nor aldosterone deficiency
prevented the Ang II–induced rise in blood urea nitrogen;
however, combined aldosterone deficiency and SPL signifi-
cantly prevented this increase. Ang II increased urine albumin
excretion in WT mice, and this effect was abrogated by SPL
treatment (Figure 4b) or aldosterone deficiency. Urinary
albumin excretion was reduced during SPL treatment in Ang
II–treated As/ mice, although this effect was not significant
(P¼ 0.07 for As/-Ang II vs. As/-Ang II–SPL group).
Ang II increased average glomerular diameter (P¼ 0.003);
this effect was prevented by SPL (P¼ 0.01 for Ang II SPL
interaction) but not by aldosterone deficiency (Figure 4c).
Ang II treatment produced significant renal injury, as
evidenced by tubular atrophy, perivascular and interstitial
fibrosis, proteinaceous intratubular casts, and occasional
glomerulosclerosis (Figure 5a). There was no effect of treat-
ment on mesangial hypercellularity, mesangial expansion, or
infiltrating inflammatory cells. Ang II treatment reduced
nephrin immunoreactivity similarly in WT and As/ mice
(from 47.5 to 31.7% in vehicle vs. Ang II treatment); SPL
restored nephrin immunoreactivity in WT and As/ mice
during Ang II treatment (42.2%; Figure 5b). Ang II treatment
increased renal arterial media area (P¼ 0.04); this was also
Table 1 | Physiologic measurements at the end of study protocol
WT-Vehicle
WT
Ang II
WT-Vehicle
SPL
WT Ang II
SPL As/-Vehicle
As/
Ang II
As/-Vehicle
SPL
As/
Ang II SPL
Body weight (g) 28.0±1.0 27.8±0.8 29.1±0.3 28.3±1.2 28.2±0.5 26.2±1.3 26.2±0.8 27.8±1.0
Serum Na+ (mEq/l) 147.7±1.1 147.2±0.9 147.5±0.3 147.5±0.5 145.5±0.6 143.0±0.3 145.2±0.7 146.2±1.1
Serum K+ (mEq/l) 5.07±0.25 5.11±0.23 5.48±0.59 5.35±0.05 5.40±0.6 5.73±0.27 5.15±0.10 5.55±0.29
HCO3
 (mEq/l) 20.1±1.4 24.5±1.7* 21.5±0.68 26.1±5.2* 21.5±1.5 24.0±2.4 21.0±1.4 21.3±1.33
Aldosterone (pg/ml) 373.0±64 484.0±165 233.0±39 883.9±458* ND# ND# ND# ND#
Corticosterone (ng/ml) 303.7±64 318.8±65 266.5±28.3 314.6±111.8 149.8±23.9 281.2±34.2 247.1±44.8 211.2±62.7
Urine Na V (mmol/day) 1043±167 4506±1534* 728±235 3776±1607* 777±126 1500±428w 1286±258 2864±1048z
Urine K V (mmol/day) 649±100 917±56 633±186 936±130 710±63 776±110 781±92 1494±426*,y
Urine Na/K ratio 1.6±0.1 4.7±1.4* 1.1±0.04 4.7±2.5 1.0±0.1 2.2±0.8 1.6±0.2 1.6±0.2w
Urine Alb/Cr (mg/g) 25.9±8.8 610.9±124.5* 11.7±0.9 171.0±120.1w 130.0±113.6 240.7±114.7w 32.5±17.2 23.9±6.0w
Abbreviations: Alb/Cr, albumin/creatinine; Ang II, angiotensin II; As/, aldosterone synthase deficient; ND, below detectable limit; SPL, spironolactone; WT, wild type.
Results are mean±s.e.m.
*Po0.05 vs. WT-vehicle, wPo0.05 vs. WT Ang II, yPo0.05 vs. As/-vehicle, zPo0.05 vs. WT Ang II SPL, #Po0.05 vs. all WT treatment groups.
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attenuated by SPL (P¼ 0.02), but not aldosterone deficiency
(Supplementary Figure S1a online). The increase in adven-
titial area in response to Ang II was prevented by SPL
treatment (P¼ 0.03), but was not affected by aldosterone
deficiency (Supplementary Figure S1b online). In contrast,
there was no effect of either SPL or aldosterone deficiency on
Ang II–induced renal fibrosis or global kidney injury score
(Supplementary Figure S1c and d online).
Profibrotic gene expression
Ang II significantly increased mRNA expression of plasmino-
gen activator inhibitor-1 (Pai-1) within cardiac, renal, and
aortic tissues (Figure 6). Either SPL or aldosterone deficiency
prevented the increase of Pai-1 mRNA expression in these
tissues to varying degrees. Cardiac preproendothelin-1 (Et-1)
expression was unchanged (Supplementary Figure S2a–c
online). Ang II increased Et-1 expression within renal tissue,
160
a b
*
*
* *
*
*
SB
P 
(m
m
H
g)
SB
P 
(m
m
H
g)140
120
100
80
160
WT-vehicle As–/–  vehicle
As–/–   Ang ll
140
120
100
80
0 2 4
Time (weeks) Time (weeks)
Regular chow Spironolactone
6 8 0 2 4 6 8
WT Ang ll
† † †
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Figure 2 |Aldosterone deficiency and MR antagonism attenuate cardiac hypertrophy and perivascular fibrosis. Angiotensin II (Ang II)
increased (a) cardiac mass and caused (b) cardiac interstitial fibrosis and (c) perivascular fibrosis in wild-type (WT) mice. Cardiac hypertrophy
was similarly abrogated in spironolactone (SPL)-treated and aldosterone synthase–deficient (As/) mice. Interstitial and perivascular
fibrosis were attenuated and not significantly increased in SPL-treated WT mice and were prevented in As/ mice. (d) Representative
images of cardiac perivascular fibrosis are shown for each treatment group; Masson trichrome (original magnification  400), Bar¼ 200mm.
*Po0.05 vs. WT-vehicle; wPo0.05 vs. WT Ang II. MR, mineralocorticoid receptor.
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and this effect was prevented by SPL but not by aldosterone
deficiency. In contrast, aldosterone deficiency was associated
with increased Et-1 expression in the aorta.
Renal 11bhsd gene expression
We analyzed renal mRNA expression of 11-bhydroxysteroid
dehydrogenase (11bhsd)-1 and 11bhsd-2 gene expression
during Ang II administration. We observed no significant
effect of Ang II on either 11bhsd-1 (1.12±0.2-fold change vs.
vehicle control; P¼ 0.84) or 11bhsd-2 (1.18±0.2; P¼ 1.0,
n¼ 5 for each group).
DISCUSSION
We found that endogenous aldosterone contributes to
Ang II/salt–induced cardiac hypertrophy, cardiac fibrosis,
and aortic remodeling through an MR-dependent mechan-
ism. In contrast, in the kidney, Ang II/salt can also induce
glomerular injury and arteriolar hypertrophy via activation
of the MR, even in the absence of endogenous aldosterone.
Ang II/salt causes renal interstitial fibrosis through an
MR- and aldosterone-independent mechanism.
Numerous studies have demonstrated that aldosterone
administration causes cardiac and aortic inflammation and
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WT-vehicle; wPo0.01 vs. WT Ang II; zPo0.05 vs. As/-vehicle; 8Po0.05 vs. WT-Ang II-SPL; yPo0.05 vs. As/-Ang II.
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remodeling, whereas MR antagonism prevents inflammation
and fibrosis in salt-treated rodents.15–20 Because endogenous
aldosterone concentrations are suppressed during high-salt
intake, and ligands other than aldosterone can activate the
MR, the absolute requirement for endogenous aldosterone in
MR-mediated pathology has been called into question.
Compelling studies in rats during excessive sodium intake
suggest an aldosterone-independent, MR-dependent mecha-
nism of cardiovascular and renal injury. For example,
MR antagonism reduces cardiac hypertrophy in the Dahl
salt-sensitive rat, a low-aldosterone model of hyper-
tension, and the authors speculated that activation of the
MR by glucocorticoids contributes to this effect.6 In the
heart, glucocorticoids may normally function as MR
antagonists under normal conditions, but contribute to
MR activation depending on the redox state of the cell.21 The
MR also contributes to diastolic dysfunction and oxidative
stress during low-dose Ang II administration, whereas
aldosterone concentrations were unchanged.22 In contrast,
we observed that either MR antagonism or genetic aldoster-
one deficiency attenuated cardiac hypertrophy and cardiac
perivascular injury, demonstrating a pivotal role for
endogenous aldosterone in this model. These data are con-
sistent with other studies testing the effect of pharmaco-
logic aldosterone synthase inhibition, and suggest that
endogenous aldosterone contributes substantially to Ang
II–induced cardiac injury.9,10,23
We have reported previously that SPL or pharmaco-
logic aldosterone synthase inhibition with FAD-286 amelio-
rated Ang II/salt–induced cardiac hypertrophy and interstitial
fibrosis but not coronary perivascular fibrosis in a rat
model.10 In this study, genetic aldosterone deficiency or SPL
prevented perivascular fibrosis as well as interstitial fibrosis
and hypertrophy, suggesting that the lack of effect in the prior
study may have been because of residual aldosterone
production during pharmacologic inhibition. The modest
and variable effect of SPL on interstitial and perivascular
fibrosis in the heart may also reflect the use of low-dose SPL.
The beneficial effect of high doses of SPL on these measures
is well established.24
We have also demonstrated previously that either FAD-
286 or SPL prevents Ang II–induced blood urea nitrogen
elevation, glomerulosclerosis, tubulointerstitial fibrosis, and
perivascular remodeling in a rat model. In this study,
although Ang II caused significant renal injury, glomerulo-
sclerosis was rare, and overall renal injury was not severe,
likely reflecting a species and strain difference. Nevertheless,
MR antagonism had selective beneficial effects on glomerular
injury, beyond the effect of aldosterone deficiency, suggesting
that activation of the MR by nonaldosterone ligands can
contribute to injury.
That MR antagonism decreases Ang II–induced renal
injury has been established previously. In humans with
diabetic nephropathy, for example, MR antagonism reduces
WT
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Vehicle Ang ll Vehicle Ang ll
Spironolactone
As–/– 
As–/– 
a
b
Figure 5 |Renal histology and nephrin immunoreactivity. Representative images of kidney histologic injury are shown for each
treatment group (a); periodic acid–Schiff (PAS) stain. Angiotensin II (Ang II) treatment decreased (b) nephrin immunoreactivity in wild-type
(WT) and aldosterone synthase–deficient (As/) mice. Original magnification  400, Bars¼ 100 mm.
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proteinuria during maximal ACE inhibition and may be
more effective than additional renin–angiotensin–aldosterone
system blockade with an Ang II receptor antagonist.3 In rats
treated with Ang II and a nitric oxide synthase inhibitor,
adrenalectomy or MR antagonism with eplerenone prevents
proteinuria and renal arteriolar and glomerular injury.25 MR
antagonism also protects against glomerular injury in salt-
sensitive rats in which plasma aldosterone is suppressed,
primarily via preserved podocyte function.7,8,26
To our knowledge, however, no studies have demonstrated
the pathologic effects of Ang II in vivo via MR activation,
while excluding the possibility of endogenous aldosterone
synthesis. Factors other than aldosterone can activate the MR
in mesangial cells and podocytes, contributing to proteinuria
and mesangial expansion. For instance, Rac1 GTPase
contributes to podocyte injury via aldosterone-independent
MR activation, producing proteinuria and renal injury.27
Conditions such as hyperglycemia, obesity, and salt loading
may activate the Rac1-MR pathway and contribute to
injury.27,28 The classical MR or a novel membrane-bound
MR may be responsible for this aldosterone-independent
signaling.29 Our data suggest that other factors also act
via the MR to produce glomerular expansion. Glucocorti-
coids can bind to and activate the MR. Normally,
glucocorticoids are inactivated by 11bHSD-2 in aldosterone
target cells.21 However, Rafiq et al.30 recently reported that
hydrocortisone causes renal injury in adrenalectomized rats
through an MR-dependent mechanism, which could result
from partial agonism of the MR in the absence of
endogenous aldosterone or from stimulation of the MR
on nonepithelial cells. There was no significant difference
in corticosterone concentrations to explain our findings.
Alternatively, metabolic products of 11bHSD-2 could act
as physiologic MR antagonists or alter the redox state of
the cell.21,31 Glomerular 11bhsd-2 mRNA expression has been
described in mesangial cells and podocytes.32,33 We found
no effect of Ang II on either 11bhsd-1 or 11bhsd-2 gene
expression in the kidney, although we did not exclude an
effect on 11bHSD-2 activity. Other investigators have also
demonstrated that Ang II activates the MR via reactive
oxygen species or NF-kB, providing another possible
explanation for these findings.22,34
In contrast to the protective effect of MR antagonism on
Ang II–induced glomerular expansion and nephrin immu-
noreactivity, neither MR antagonism with SPL nor aldoster-
one deficiency prevented Ang II/salt–induced renal interstitial
fibrosis in this study. These findings are consistent with an
AT1 receptor–dependent profibrotic effect of Ang II, as other
investigators have demonstrated.35 The data are also
consistent with the finding that SPL decreases glomerular
injury, but not interstitial fibrosis.8
Multiple studies have demonstrated the central impor-
tance of PAI-1 as a profibrotic mediator in renal, vascular,
and cardiac tissues.36 Although Ang II is a classic stimulus for
Pai-1 gene expression, aldosterone and the MR are essential
for a maximal response in certain tissues. We reported
previously that endogenous aldosterone contributes to the
effect of acute Ang II infusion on Pai-1 mRNA expression
within the heart, but not in aorta.13 During chronic Ang II
exposure, endogenous aldosterone appears to contribute to
increased Pai-1 expression within both the heart and the
aorta via the MR. The concordant pathologic effects suggest a
central role for aldosterone, the MR, and PAI-1, and suggest
that improvement in our model could be accomplished via
reduction of Pai-1 expression.
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Figure 6 | Tissue plasminogen activator inhibitor-1 mRNA
expression. Angiotensin II (Ang II) treatment increased
plasminogen activator inhibitor-1 (Pai-1) mRNA levels in (a) cardiac,
(b) aortic, and (c) renal tissues in wild-type (WT) mice.
Spironolactone (SPL) or genetic aldosterone synthase deficiency
(As/) prevented this increase within the heart and aorta, and
attenuated the effect within the kidney. *Po0.05 vs. WT-vehicle;
wPo0.05 vs. WT-Ang II; zPo0.05 vs. As/-vehicle-SPL.
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Finally, genetic aldosterone deficiency resulted in a
blunted pressor response to Ang II; decreased blood pressure
may have contributed to the protective effect of aldosterone
deficiency on cardiovascular remodeling. This underscores
the lack of protective effect of aldosterone deficiency on
glomerular expansion. Similarly, the pressor response to Ang
II was similar in As/-Ang II and WT-SPL–Ang II groups,
suggesting that differences between the effects of MR
antagonism and aldosterone deficiency on renal injury were
blood pressure independent.
Renin–angiotensin–aldosterone system blockade with
either ACE inhibitors or Ang II receptor antagonists prevents
cardiovascular and renal events in high-risk individuals, and
SPL provides additional benefit beyond ACE inhibition.3–5
Although ACE inhibition reduces circulating Ang II levels,
other enzymes such as chymase contribute to local Ang II
generation via an alternative pathway.37 Although it is well
established that aldosterone produces MR-mediated injury,
other Ang II–induced ligands may also activate the MR and
contribute to tissue injury. This study demonstrates that
aldosterone mediates a portion of Ang II–induced cardiac,
renal, and vascular injury and profibrotic gene expression.
The additional benefit of MR antagonism in the setting of
aldosterone deficiency suggests that Ang II can also mediate
MR-dependent effects in vivo in the absence of aldosterone.
Therefore, MR antagonism may provide additional beneficial
effects regardless of circulating aldosterone concentrations.
MATERIALS AND METHODS
Animals
All experiments were reviewed and approved by the Vanderbilt
University Institutional Animal Care and Use Committee. As/
mice were generated on a 129 background38 and backcrossed over
seven generations onto the C57Bl6/J strain (Jackson Laboratory, Bar
Harbor, ME). Mice were genotyped by real-time PCR (Applied
Biosystems 7900HT, Foster City, CA) using Taqman probes for a
sequence in the Cyp11b2 gene and for a portion of the gene
contained in the neomycin-resistance cassette as previously
described.13 Male As/ and WT littermates were studied. Animals
were housed in a temperature-controlled facility with a 12-h light/
dark cycle. Mice were maintained on 0.9% saline in the drinking
water ad libitum starting at age 8 weeks and continued for the
duration of the study.
Chronic Ang II infusion protocol
At 12 weeks of age, mice were randomized to treatment with Ang II,
SPL, or a combination of both. Ang II (1mg/h, CalBiochem, La Jolla,
CA) or vehicle were delivered by osmotic minipumps (Alzet Model
2001, Alza, Palo Alto, CA) implanted under pentobarbital anesthesia
(50 mg/kg intraperitoneally) at 12 weeks of age. This dose of
Ang II was chosen to induce modest hypertension and injury in WT
mice.39 After pump implantation, mice received either standard
mouse chow (Purina Laboratory Rodent 5001, St Louis, MO) or
standard chow supplemented with SPL, continued for the duration
of the study. SPL chow was formulated by TestDiet (Richmond, IN)
at concentrations to provide 6 mg/kg/day based on prior studies
demonstrating that this dose decreases end-organ damage.10,40
Minipumps were replaced after 4 weeks.
Mice were killed 8 weeks after initial minipump implantation
(20 weeks of age). Cervical dislocation was performed, the left renal
artery was clamped, and blood was collected by cardiac puncture
and transferred into a tube containing dipotassium-EDTA tubes
(Microvette CB K2E, Sarstedt AG, Numbrecht, Germany). The
base of the heart, the first 2 mm of descending aorta, and coronal
sections of the kidney were fixed in 4% buffered paraformaldehyde
overnight, transferred to 70% ethanol, and then embedded in
paraffin for histological evaluation. The remainder of the heart, liver,
and kidney were snap-frozen in liquid nitrogen for mRNA
extraction. The remaining aorta (descending aorta to above the
renal arteries) was transferred into fresh phosphate-buffered saline
solution, stripped of adventitial tissue, collected into RNALater
solution (Ambion, Austin, TX) at 4 1C overnight, and then
transferred to a vial for storage at 80 1C.
Cardiovascular measurements
Blood pressure was measured every 2 weeks starting at 6–8 weeks
of age (X4 weeks before randomization) using automated tail-cuff
impedance plethysmography (BP-2000 Blood Pressure Analysis
System; Visitech Systems, Apex, NC) in unanesthetized, trained
mice, pre-warmed for 5 min at 37 1C. At 20 weeks of age, trans-
thoracic echocardiography was performed in conscious mice using
a 15-MHz transducer (Sonos 5500 system, Agilent, Andover, MA)
as previously published.41
Blood and urine chemistry
Blood was obtained for chemistry after 8 weeks of treatment, before
killing. Mice were fasted in a clean cage at 0900 h, and 50 ml whole
blood was collected at 1300–1500 h via saphenous vein into a
heparinized capillary tube (Microvette CB K2E, Sarstedt AG) and
processed immediately by iSTAT EC8þ cartridge (Heska, Loveland,
CO). An additional 30 ml of blood was collected into dipotassium-
EDTA (Microvette CB K2E, Sarstedt AG) and centrifuged at
6000 r.p.m. for 5 min. Plasma was stored at 80 1C until assay.
Aldosterone was determined using a radioimmunoassay utilizing
125I-aldosterone (MP Biomedicals, Irvine CA), a primary antibody
to aldosterone (NIDDK National Hormone & Peptide Program,
Torrance, CA), and a secondary anti-rabbit g-globulin antibody
(Linco Research, St Charles, MO). Corticosterone was measured
using a commercially available radioimmunoassay kit (ImmuChem
Double Antibody Corticosterone Kit, MP Biomedicals).
For urine collection, mice were housed in individual metabolic
cages (Nalgene Labware, Rochester, NY) for 24 h. Urine was
collected while mice were ingesting normal chow and 0.9% saline
ad libitum during the final week of treatment (that is, Ang II, SPL).
Urine Naþ and Cl were measured by flame photometry (ILS 940).
Urine was analyzed for albumin using an immunoturbidimetric
assay and for creatinine by a modified colorimetric assay that
correlates well with HPLC-based methods (DCA 2000þ Analyzer
and Microalbumin/Creatinine cartridges, Bayer, Elkhart, IN).42
Histopathologic analysis
Images were captured on a Zeiss AxioScop 40 using MRGrab 1.0
(Media Cybernetics, Silver Spring, MD). All quantitative image
analyses were performed using ImageJ, version 1.40g (NIH,
Bethesda, MD),43 and all image measurements were calibrated
using a 2 mm slide micrometer photographed under appropriate
magnification.
Glomerular area and diameter were determined by outlining
30–50 consecutive glomeruli per animal (imaged using  40
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objective), for 3–4 animals per group. Renal media and perivascular
area were measured by tracing the inner lumen, outer border of the
tunica media, and outer border of the adventitial area ( 50
objective, 3–5 interlobular arteries per animal). Collagen area was
quantified by picro-sirius red staining imaged under cross-polarized
light, measured as percentage of collagen-positive area, excluding
hilar vessels from the analysis. Aortic intima–media and adventitia
thickness are averages from X4 linear measurements per aorta.
An investigator (ABF) blinded to treatment assignment also
assessed histopathology. Kidney injury was scored semiquantita-
tively on Masson trichrome–stained sections, from 0 to 3 for each
high-power field (0 indicating no injury; 1 indicating single small
focus of fibrosis; 2 indicating several small foci; 3 indicating
multifocal fibrosis). Cardiac interstitial fibrosis was scored semi-
quantitatively as an estimate of percentage of fibrotic area. Cardiac
perivascular fibrosis was scored semiquantitatively (0 indicating
no fibrosis; 1 indicating adventitial fibrosis less than media area;
2 indicating fibrosis equal to media area; and 3 indicating fibrosis
greater than media area).
Nephrin immunohistochemistry was performed after citrate
buffer antigen retrieval, using an anti-mouse nephrin primary
antibody (R&D Systems AF3159, Minneapolis, MN), biotinylated
secondary antibody (Vector Labs BA-5000, Burlingame, CA), and
detection with the VECTASTAIN ABC kit (Vector Labs). Nephrin-
positive glomerular area was measured in 15–20 glomeruli per
animal using ImageJ software.
Gene expression
Cardiac, hepatic, and renal total RNAs were extracted using RNA
Wiz (Ambion) and RNeasy Midi Kit (Qiagen, Valencia, CA), and
aortic RNA was extracted with RNeasy Mini Kit (Qiagen). Reverse
transcription was performed using TaqMan Reverse Transcription
Kit (Applied Biosystems, Branchburg, NJ). Quantitative real-time
PCR was performed in duplicate on the iCycler iQ Multi-Color Real
Time PCR Detection System (Bio-Rad, Hercules, CA) using iQ
SYBR Green Supermix (Bio-Rad) using primers as previously
described and 50 ml total reaction volume.39 Template cDNA used in
the reaction was 2 mg for heart and kidney and 500 ng for aorta.
Experimental cycle threshold (Ct) values were normalized to b-actin
measured on the same plate, and fold differences in gene expression
were determined using the 2DDCt method.44
Statistics
Data are presented as mean±s.e.m. Comparisons among treatment
groups were performed using analysis of variance, with least
significant difference post hoc testing for between-group pairs.
Because not all pair-wise comparisons are of physiologic relevance
and normality could not be assumed, we confirmed significant
between-group differences using nonparametric tests. Wilcoxon
signed-rank test and Wilcoxon rank-sum test were used for paired
and unpaired comparisons, respectively, for any nonnormally
distributed data. Individual drug effect and drug–genotype interac-
tion for injury measures were assessed by multivariable linear
regression with genotype, Ang II treatment, and SPL treatment as
exposure variables. All statistical analyses were performed using
SPSS for Windows, version 17.0 (SPSS, Chicago, IL), or the open
source statistical package R, version 2.11.1.45 A two-tailed P-value of
o0.05 was considered significant.
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SUPPLEMENTARY MATERIAL
Figure 1. Interlobular artery media (A) and adventitial area (B)
increased during angiotensin (Ang) II (P¼ 0.04), and this was attenuated
by spironolactone (SPL) (P¼ 0.02), but not aldosterone deficiency.
Figure 2. Prepro-endothelin (Et-1) mRNA levels in cardiac tissues (A)
were unchanged during Ang II treatment.
Supplementary material is linked to the online version of the paper at
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